A founder treated as a vendor, repositioned as a clinical peer
We replaced the product pitch with a category claim clinicians could argue with, published it where medical directors already read, and turned cold enterprise outreach into inbound pilot conversations.
- 4
- health systems inbound
- 2
- signed pilots
- 9 mo
- to first inbound pilot
A funded product, a founder with real operational depth, and a public record that read like a brochure. Every enterprise conversation began from zero trust, and outbound response rates were falling.
We narrowed the company to one defensible claim about workflow, and put the CEO in front of it in writing. Everything published was aimed at medical directors and CMIOs rather than at investors or the tech press.
Clinical leaders started forwarding the writing internally. Four health systems opened conversations without a rep, two converted to paid pilots, and the security and procurement stages moved faster because the name was already familiar.
- One category claim instead of a feature list.
- Executive writing that survived clinical scrutiny.
- Evidence framed the way a buying committee reads it.
- A named account list worked through relationships, not sequences.
Every deal that moved had started with someone who already knew them. So we made far more people know them.
The deck was strong. The problem was that nobody had heard the argument behind it until the meeting started.
The company had clinical credibility sitting in one person. Nobody outside the building could see it.